Britannia Life Sciences Inc. Announces $10 Million Debenture Offering to Provide Investor Access to Asset-Backed Loan Portfolio
Toronto, Ontario–(Newsfile Corp. – July 28, 2025) – Britannia Life Sciences Inc. (CSE: BLAB) (“Britannia” or the “Company”) is pleased to announce the launch of a non-brokered private placement offering of unsecured debentures (the “Debentures”) for gross proceeds of up to $10 million CAD.
The proceeds from the offering will be used to provide debenture holders of Britannia with exposure to a fixed return generated by a portfolio of asset-backed loans, offering strong underlying collateral backing and monthly interest income, beginning after an initial 60 day deployment period.
Further to the Company’s release on July 8, 2025, the initiative represents Britannia’s continued expansion into the specialty finance sector, leveraging its platform to originate and administer investments in private debt and non-resource royalty markets to generate attractive income streams for its shareholders.
The Debentures will not be convertible, and will:
- Bear interest at 18% per annum, paid monthly subject to a 60 day delayed accrual;
- Have a 10-year term from the date of issuance;
- Be listed on the CSE (subject to prior satisfaction of all CSE listing requirements with respect to the Debentures);
- Be redeemable by the Company after 2 years at 101% of the then-prevailing market price;
- Be offered in minimum subscriptions of $50,000.
“This offering allows Britannia to provide accredited and institutional investors with direct exposure to an arm’s-length portfolio of asset-backed, income-generating assets,” said Peter Shippen, CEO of Britannia Life Sciences Inc. “By focusing on unique opportunities in underserved markets we’re able to deliver attractive yields while still being supported by high-quality collateral.”
The Debentures will be offered by private placement to eligible investors in reliance on applicable exemptions from prospectus requirements under Canadian securities laws. The securities issued pursuant to the offering will be subject to a four-month hold period under applicable Canadian securities laws. The offering is expected to close on or before September 15, 2025 and remains subject to customary closing conditions and any required regulatory approvals, including approval of the CSE.
About Britannia Life Sciences Inc.
Britannia Life Sciences Inc. is a diversified services platform operating across North America and Europe. Historically anchored in science-based services-such as laboratory testing and regulatory compliance – the company recently sold its U.K. laboratory business and is repositioning its expertise and infrastructure for broader opportunities. Management is actively exploring how the existing platform can be applied to the growing markets for private debt and non-resource royalties and is considering a rebrand to better reflect this wider strategic focus beyond the life-sciences sector.
For further information, please contact:
Peter Shippen, CEO
Britannia Life Sciences Inc.
416-930-7711
Email: enquiries@britannia.life
Website: www.britannia.life